Emergent BioSolutions to acquire anthrax treatment, move manufacturing to Baltimore

Emergent BioSolutions to acquire anthrax treatment, move manufacturing to Baltimore

Emergent BioSolutions, a Gaithersburg-based drug maker with facilities in Baltimore, has acquired a drug used to treat anthrax from GlaxoSmithKline in a deal worth up to $96 million. Under the deal announced Wednesday, Emergent will pay $76 million cash upfront and up to $20 million in product sales and milestone payments to acquire Raxibacumab, a drug used to treat inhaled add to Emergent's portfolio of countermeasures for infectious diseases and advance the company's goal of growing business at its recently expanded Baltimore manufacturing facility.

from Biotech News